Novo Nordisk A/S Sponsored ADR Class B (NVO.US) Q3 sales increased 11% year-on-year.

On Wednesday, Danish pharmaceutical giant Novo Nordisk A/S Sponsored ADR Class B (NVO.US) announced its financial report for the third quarter of 2025. The third quarter sales revenue (calculated at fixed exchange rates) increased by 11% year-on-year to DKK 74.976 billion; operating profit (calculated at fixed exchange rates) decreased by 21% year-on-year to DKK 23.682 billion; net profit was DKK 20.006 billion, a decrease of 27% compared to the same period last year. The financial report shows that the sales revenue for the diabetes and weight loss drug business of Novo Nordisk A/S Sponsored ADR Class B in the third quarter was DKK 70.26 billion. Among them, Ozempic's sales revenue was DKK 30.74 billion; the oral GLP-1 drug Rybelsus' sales revenue was DKK 5.44 billion; Wegovy's sales revenue was DKK 20.35 billion. The sales revenue of Semaglutide in the first three quarters was DKK 169.296 billion (USD 25.4 billion), surpassing K drug (USD 23.3 billion) and Lilly's tirzepatide (USD 24.8 billion). At the same time, the company updated its performance guidance. Novo Nordisk A/S Sponsored ADR Class B stated that, calculated at fixed exchange rate, sales revenue is expected to increase by 8%-11% in 2025, and operating profit is expected to increase by 4%-7%. Novo Nordisk A/S Sponsored ADR Class B CEO Mike Doustdar stated that they are taking aggressive strategies to streamline organizational structure and refocus on the core business of diabetes and weight loss. Earlier, Novo Nordisk A/S Sponsored ADR Class B increased its acquisition offer for the U.S. weight loss drug startup company Metsera (MTSR.US), with the latest offer reaching USD 10 billion. It is reported that Metsera is one of the most promising companies in the weight loss drug industry, developing multiple experimental weight loss drugs, including an innovative drug with injection frequency possibly lower than existing products from Novo Nordisk A/S Sponsored ADR Class B and Lilly.